A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765 (AZD6765 EEG)
A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Rouffach, France
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI 18-30 Non-smoker for at least 4 weeks
Exclusion Criteria:
- Any clinically relevant acute or chronic disease
- History of substance abuse Hypersensitivity to ketamine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AZD6765 75 mg
|
75 mg
150 mg
|
|
Experimental: AZD6765 150 mg
|
75 mg
150 mg
|
|
Active Comparator: Ketamine 0.5 mg/kg
|
0.5 mg/kg
|
|
Placebo Comparator: 125 mL sterile NaCl 0.9%
|
125 mL sterile NaCl 0.9%
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
qEEG assessed through the gamma bands
Time Frame: Day 1 of each treatment period at Predose, 0.25h, 1h, 1.25h, 3h and 8h
|
Day 1 of each treatment period at Predose, 0.25h, 1h, 1.25h, 3h and 8h
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pupil Size - to assess the relationship between qEEG and pupil size
Time Frame: Day 1 of each treatment period at Predose, 0.25h, 1h, 1.25h, 3h, and 8h
|
Day 1 of each treatment period at Predose, 0.25h, 1h, 1.25h, 3h, and 8h
|
|
Electronystagmography - to assess the relationship between qEEG and spontaneous nystagmus.
Time Frame: Day 1 of each treatment period at Predose, 1h, 3h, and 8h
|
Day 1 of each treatment period at Predose, 1h, 3h, and 8h
|
|
Bond/Lader scales and eVAS - to assess the subject's alertness, calmness and contentment
Time Frame: Day 1 of each treatment period at Predose, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, and 8h
|
Day 1 of each treatment period at Predose, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, and 8h
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Albena Patroneva, MD, AstraZeneca
- Principal Investigator: Francine Santoro, FORENAP
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
Other Study ID Numbers
- D2285M00008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.